GlassScriptPhysician profile
Devin Alexander Stein
NPI 1881297182
$5,203.42
in general payments reported to CMS, 2019-2025
22 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,198 · 2022: $1,331 · 2023: $783 · 2024: $365 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $61.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.47 |
| Education | $61.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,116.72 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $864.91 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $659.39 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $373.97 | 2021-2025 | Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $373.59 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $323.93 | 2021-2025 | Caplyta |
| Lundbeck LLC | $238.29 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $197.55 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $185.71 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.96 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $141.52 | 2022-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $115.18 | 2021-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $103.05 | 2025 | Dyanavel Xr, Onyda Xr |
| E.R. Squibb & Sons, L.L.C. | $90.14 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $80.09 | 2021-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $77.78 | 2022-2025 | Azstarys |
| Noven Therapeutics, LLC | $20.07 | 2022 | |
| Neos Therapeutics, LP | $18.69 | 2022 | |
| Biogen, INC. | $17.82 | 2024 | |
| Ironshore Pharmaceuticals INC. | $15.17 | 2023 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $13.41 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.